SCHEMBL3298250

SCHEMBL3298250

COc1ccc(CNc2nc3c(c(=O)n2-c2ccccc2)CN(C(=O)Nc2ccccc2C(=O)O)CC3)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRLHR P49683 5/20 0.45
MAPT P10636 6/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
HCAR2 Q8TDS4 2/20 0.42
CLPP Q16740 1/20 0.42
ALDH1A1 P00352 4/20 0.42
RECQL P46063 1/20 0.40
PPARG P37231 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
POLB P06746 1/20 0.39
PDE5A O76074 1/20 0.39
KDM4E B2RXH2 2/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PDE10A Q9Y233 1/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3296765 0.92 PRLHR (0.46) PRLHRMAPTL3MBTL1KMT2ACLPP
SCHEMBL3295383 0.91 PRLHR (0.49) PRLHRMAPTL3MBTL1KMT2ACLPP
SCHEMBL3301167 0.90 PRLHR (0.48) PRLHRMAPTCLPPALDH1A1RECQL
SCHEMBL3297692 0.89 PRLHR (0.47) PRLHRMAPTL3MBTL1KMT2ACLPP
SCHEMBL3296546 0.89 PRLHR (0.46) PRLHRMAPTL3MBTL1KMT2ACLPP
SCHEMBL3299059 0.88 PRLHR (0.49) PRLHRMAPTCLPPALDH1A1RECQL
SCHEMBL3303387 0.88 PRLHR (0.46) PRLHRMAPTL3MBTL1KMT2ACLPP
SCHEMBL3301556 0.88 PRLHR (0.43) PRLHRMAPTL3MBTL1KMT2ACLPP
SCHEMBL3296568 0.87 PRLHR (0.45) PRLHRMAPTL3MBTL1KMT2ACLPP
SCHEMBL17358374 0.87 RECQL (0.48) PRLHRMAPTKMT2ACLPPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232282-B2 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-31 US disclosed
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-15 US disclosed
EP-2078719-A1 COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same GART, MGAT2, MGAT1 PRLHR 3093/4885MAPT 2514/4885L3MBTL1 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.